Drugs News and Research

RSS

Health care costs of abused women change from year to year after abuse ends: Study

Victims of domestic violence endure significantly higher health costs than other women for three years after the abuse ends, a new study finds.

27 Apr 2010

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite increased competition from several emerging agents, GlaxoSmithKline's Advair will remain surveyed pulmonologists' and primary care physicians' (PCPs) favored fixed-dose long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combination inhaler through 2013 for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

27 Apr 2010

Vital stem cells extracted during heart bypass surgery can help repair damaged heart muscle: BHF

Scientists have for the first time succeeded in extracting vital stem cells from sections of vein removed for heart bypass surgery. Researchers funded by the British Heart Foundation found that these stem cells can stimulate new blood vessels to grow, which could potentially help repair damaged heart muscle after a heart attack.

27 Apr 2010

Jefferson Medical College surgeon uses artificial liver assist device as bridge to transplantation

Cataldo Doria, M.D., Ph.D., Nicoletti Family Professor of Transplant Surgery at Jefferson Medical College of Thomas Jefferson University, and director of the Division of Transplantation at Thomas Jefferson University Hospital is the first transplant surgeon in the United States to use a new totally artificial liver assist device as a bridge to transplantation.

27 Apr 2010

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

Ipsen, a global biopharmaceutical group, and Invida Group, the leading healthcare commercialization solutions partner in the Asia Pacific region, announced today an agreement for the exclusive distribution and promotion by Invida of Ipsen's drugs Diphereline® 3.75mg & 11.25mg, Somatuline® Autogel® and Increlex® in selected countries in South-East Asia.

27 Apr 2010

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

Scientists at Australia's Burnet Institute have developed a rapid point-of-care diagnostic test for the measurement of CD4 T-cells, a marker of the immune system for people living with HIV and AIDS.

27 Apr 2010

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, has received a grant of US$500,000 for its on-going Phase II clinical trial of DIABECELL in New Zealand from the Juvenile Diabetes Research Foundation International, a world leader in setting the agenda for diabetes research and the largest charitable funder and advocate for research in type 1 diabetes.

27 Apr 2010

Tel Aviv University researcher maps drug target to wipe pain away

In most cases of chronic pain -- lingering pain that never seems to go away after accidents or prolonged illnesses ― no pill exists to dull the hurt. Billions of dollars are lost every year in sick days taken to alleviate chronic pain, and as much money is spent by the healthcare system to diagnose what's wrong.

27 Apr 2010

Military trauma transition units breed culture of drug abuse, depression

The New York Times reports on a Warrior Transition Battalion unit in Colorado used by the military to transition injured veterans back into the military or their home lives. "Created in the wake of the scandal in 2007 over serious shortcomings at Walter Reed Army Medical Center, Warrior Transition Units were intended to be sheltering way stations where injured soldiers could recuperate and return to duty or gently process out of the Army.

27 Apr 2010

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Logical Therapeutics, Inc., a Waltham, Mass.-based biotechnology company announced today the initiation of a Phase 2b clinical study to evaluate the gastrointestinal safety of its investigational drug LT-NS001 (naproxen etemesil). The study will compare the cumulative rate of gastric ulcers vs. Naprosyn after 12 weeks of treatment.

27 Apr 2010

Costs, effects on business questioned as health overhaul analysis continues

The Associated Press: The biggest unanswered question in the health overhaul debate remains what the new law will mean for ordinary Americans. "Many experts believe the law falls short on taming costs, and that will force Congress to revisit health care in a few years.

27 Apr 2010

Stinging FDA review for Acurox – the implications

The US FDA’s advisory panel’s decision to recommend against approval of Acura Pharmaceuticals/King Pharmaceuticals’ Acurox (oxycodone plus niacin) was based upon the view that data were lacking that niacin-induced flushing could potentially reduce misuse of Acurox with single-ingredient oxycodone. The panel also contended that clinical studies were not conducted in populations that might be likely to benefit from the drug’s purported abuse-deterrent properties, such as those with chronic pain and adolescents who are experimenting with drug use.

27 Apr 2010

Nurses interrupted – leading to 12% rise in medication errors: study

In a study published in the journal Archives of Internal Medicine on the 26th of April the causes of “procedural failure and clinical error” by nurses in Australian hospitals were analyzed. The study found that nurses made at least one mistake or oversight in a whopping 80.2% of cases where they were administering drugs or other therapy to patients. These mistakes could range from not checking the patient’s identity before giving the drug to not washing hands. Researchers say that in some cases these mistakes could be fatal.

27 Apr 2010

PRTT completes acquisition of multiple patents and patents-pending from Nectid

Pro-Tect Pharmaceuticals, Inc. announced that it has completed the acquisition of multiple patents and patents-pending from Nectid, Inc., that enable three revolutionary drug delivery technologies.

26 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

Covidien launches EXALGO Extended-Release Tablets in the US

Covidien, a leading global provider of healthcare products, today introduced EXALGO™ (hydromorphone HCI) Extended-Release Tablets, (CII), the only extended-release hydromorphone treatment available in the United States. This proven therapy, combined with an innovative delivery system, provides opioid-tolerant patients suffering from moderate-to-severe chronic pain relief for 24 hours per dose.

26 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Researchers synthesize metal compounds that can be effective in treatment of cancer

Scientists from Bochum have managed to accurately determine the location of metal complexes within living cancer cells using Raman microscopy. The researchers have thus gained new insights into the mechanism of action of metal-containing drugs, to which they ascribe great potential capacities, e.g. in the treatment of cancer.

26 Apr 2010

Research documents early warning signs resulting from global pullback on AIDS funding

Rationing Funds, Risking Lives: World Backtracks on HIV Treatment, the new report from the International Treatment Preparedness Coalition, documents early warning signs resulting from the global pullback on AIDS commitment and funding: caps on the number of people enrolled in treatment programs, more frequent drug stock outs, and national AIDS budgets falling short.

26 Apr 2010

Drugs News and Research

Health care costs of abused women change from year to year after abuse ends: Study

Advair to remain favored fixed-dose LABA/ICS combination therapy through 2013 for asthma and COPD

Vital stem cells extracted during heart bypass surgery can help repair damaged heart muscle: BHF

Jefferson Medical College surgeon uses artificial liver assist device as bridge to transplantation

Invida to distribute and promote Ipsen's Diphereline, Somatuline Autogel and Increlex in South-East Asia

Scientists develop rapid point-of-care diagnostic test to measure CD4 T-cells

LCT receives grant of $500,000 for Phase II clinical trial of DIABECELL in New Zealand

Tel Aviv University researcher maps drug target to wipe pain away

Military trauma transition units breed culture of drug abuse, depression

Phase 2b clinical study initiated to evaluate GI safety of LT-NS001

Costs, effects on business questioned as health overhaul analysis continues

Stinging FDA review for Acurox – the implications

Nurses interrupted – leading to 12% rise in medication errors: study

PRTT completes acquisition of multiple patents and patents-pending from Nectid

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Covidien launches EXALGO Extended-Release Tablets in the US

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

Researchers synthesize metal compounds that can be effective in treatment of cancer

Research documents early warning signs resulting from global pullback on AIDS funding

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News